Q1 Earnings Forecast for Genmab A/S Issued By HC Wainwright

Genmab A/S (NASDAQ:GMAB - Free Report) - Research analysts at HC Wainwright lifted their Q1 2025 earnings estimates for shares of Genmab A/S in a note issued to investors on Thursday, April 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.21 per share for the quarter, up from their prior estimate of $0.18. HC Wainwright has a "Buy" rating and a $37.00 price objective on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S's Q2 2025 earnings at $0.44 EPS, Q3 2025 earnings at $0.45 EPS and FY2026 earnings at $1.85 EPS.

A number of other research analysts also recently issued reports on the company. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Truist Financial reduced their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Finally, Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Genmab A/S presently has a consensus rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Trading Up 1.4 %

Shares of Genmab A/S stock traded up $0.29 during trading on Friday, reaching $21.08. The stock had a trading volume of 845,376 shares, compared to its average volume of 1,509,329. The company has a market capitalization of $13.52 billion, a price-to-earnings ratio of 12.11, a P/E/G ratio of 2.65 and a beta of 1.07. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $30.41. The stock has a fifty day moving average price of $20.41 and a two-hundred day moving average price of $21.00.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC raised its holdings in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC raised its holdings in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after buying an additional 950 shares during the last quarter. GAMMA Investing LLC raised its holdings in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after buying an additional 1,051 shares during the last quarter. Barclays PLC raised its holdings in Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC raised its holdings in Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after buying an additional 2,496 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.